Gut microbiome: a key driver and therapeutic target of intestinal fibrosis in Crohn's disease.
It is suggested that targeting the microbiome-fibrosis axis, through precision modulation of the microbiome or metabolite-based interventions, represents a promising frontier for preventing and reversing fibrostenotic Crohn's disease.